AI assistant
EyePoint Pharmaceuticals, Inc. — Director's Dealing 2023
Feb 13, 2023
32254_dirs_2023-02-13_fa14e8e9-4b82-4d8a-b8d4-8bee9672ca5a.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: EyePoint Pharmaceuticals, Inc. (EYPT)
CIK: 0001314102
Period of Report: 2023-02-09
Reporting Person: Jones David Scott (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2023-02-09 | Common Stock | M | 4967.00 | $0.00 | Acquired | 23089.00 | Direct |
| 2023-02-09 | Common Stock | M | 5000.00 | $0.00 | Acquired | 28089.00 | Direct |
| 2023-02-09 | Common Stock | F | 1483.00 | $4.17 | Disposed | 26606.00 | Direct |
| 2023-02-09 | Common Stock | F | 1473.00 | $4.17 | Disposed | 25133.00 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2023-02-09 | Restricted Stock Units | $0.00 | M | 5000.00 | Disposed | Common Stock (5000.00) | Direct | |
| 2023-02-09 | Restricted Stock Units | $0.00 | M | 4967.00 | Disposed | Common Stock (4967.00) | Direct |
Footnotes
F1: Includes 825 shares acquired on July 31, 2022 and 1,698 shares acquired on January 31,2023 pursuant to EyePoint's 2019 Employee Stock Purchase Plan.
F2: No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of their withholding right following the vesting of the restricted stock units.
F3: The restricted stock units vest in three annual installments beginning February 9, 2023.
F4: The restricted stock units vest in three ratable annual installments beginning February 9, 2022.